Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites

Journal of Gastroenterology

Volumn 51, Issue 6, 2016, Pages 620-627

  Nakanishi, Hiroyuki ^a   Kurosaki, Masayuki ^a   Hosokawa, Takanori ^a   Takahashi, Yuka ^a   Itakura, Jun ^a   Suzuki, Shoko ^a   Yasui, Yutaka ^a   Tamaki, Nobuharu ^a   Nakakuki, Natsuko ^a   Takada, Hitomi ^a   Higuchi, Mayu ^a   Komiyama, Yasuyuki ^a   Yoshida, Tsubasa ^a   Takaura, Kenta ^a   Hayashi, Tsuguru ^a   Kuwabara, Konomi ^a   Sasaki, Sei ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Ascites; Hyponatremia; Tolvaptan; Urinary aquaporin 2

Indexed keywords

ALBUMIN; AQUAPORIN 2; CREATININE; DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE; TOLVAPTAN; VASOPRESSIN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIURETIC THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUID RETENTION; GYNECOMASTIA; HUMAN; HYPERNATREMIA; LIVER CIRRHOSIS; MALE; OSMOLARITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; URINARY EXCRETION; URINE LEVEL; WATER ABSORPTION; WEIGHT REDUCTION; COMPLICATION; MIDDLE AGED; RETROSPECTIVE STUDY; URINE;

AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; AQUAPORIN 2; ASCITES; BENZAZEPINES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84948431082     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1143-3     Document Type: Article

References (36)

1. Sola E, Watson H, Graupera I, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol. 2012;57(6):1199–206.
2. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646–54.
3. Gines P, Jimenez W, Arroyo V, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology. 1988;8(3):636–42.
4. La Villa G, Romanelli RG, Casini Raggi V, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology. 1992;16(1):156–61.
5. Arroyo V, Bosch J, Mauri M, et al. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Investig. 1979;9(1):69–73.
6. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982;96(4):413–7.
7. Claria J, Jimenez W, Arroyo V, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology. 1989;97(5):1294–9.
8. Claria J, Jimenez W, Arroyo V, et al. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology. 1991;100(2):494–501.
9. Asahina Y, Izumi N, Enomoto N, et al. Increased gene expression of water channel in cirrhotic rat kidneys. Hepatology. 1995;21(1):169–73.
10. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature. 1993;361(6412):549–52.
11. Sasaki S, Fushimi K, Saito H, et al. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. J Clin Investig. 1994;93(3):1250–6.
12. Radin MJ, Yu MJ, Stoedkilde L, et al. Aquaporin-2 regulation in health and disease. Vet Clin Pathol. 2012;41(4):455–70.
13. Sasaki S. Aquaporin 2: from its discovery to molecular structure and medical implications. Mol Aspects Med. 2012;33(5–6):535–46.
14. Brown D, Hasler U, Nunes P, Bouley R, Lu HA. Phosphorylation events and the modulation of aquaporin 2 cell surface expression. Curr Opin Nephrol Hyperten. 2008;17(5):491–8.
15. Kanno K, Sasaki S, Hirata Y, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med. 1995;332(23):1540–5.
16. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004;101(36):13368–73.
17. Rai T, Sekine K, Kanno K, et al. Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol. 1997;8(9):1357–62.
18. Sasaki S, Ohmoto Y, Mori T, Iwata F, Muraguchi M. Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method. Clin Exp Nephrol. 2012;16(3):406–10.
19. Ivarsen P, Frokiaer J, Aagaard NK, et al. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut. 2003;52(8):1194–9.
20. Elliot S, Goldsmith P, Knepper M, Haughey M, Olson B. Urinary excretion of aquaporin-2 in humans: a potential marker of collecting duct responsiveness to vasopressin. J Am Soc Nephrol. 1996;7(3):403–9.
21. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33–45.
22. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319–31.
23. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297(12):1332–43.
24. Hori M. Tolvaptan for heart failure patients with volume overload. Cardiovasc Drug Ther. 2011;25(Suppl 1):S1–4.
25. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112.
26. Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44(1):73–82.
27. Zhang X, Wang SZ, Zheng JF, et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol. 2014;20(32):11400–5.
28. 2-receptor antagonist tolvaptan. Dig Dis Sci. 2012;57(11):2774–85.
29. Okita K, Kawazoe S, Hasebe C, et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44(1):83–91.
30. Kogiso T, Tokushige K, Hashimoto E, et al. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatol Res. 2015. doi:10.1111/hepr.12547.
31. Ohki T, Sato K, Yamada T, et al. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015;7(12):1685–93.
32. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397–417.
33. Hernandez-Guerra M, Garcia-Pagan JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol. 2005;39(4 Suppl 2):S131–7.
34. Epstein FH. Underfilling versus overflow in hepatic ascites. N Engl J Med. 1982;307(25):1577–8.
35. Esteva-Font C, Baccaro ME, Fernandez-Llama P, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44(6):1555–63.
36. Chung SH, Jun DW, Kim KT, et al. Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. Dig Dis Sci. 2010;55(4):1135–41.